Subtype selective kainic acid receptor agonists: Discovery and approaches to rational design

Medicinal Research Reviews

Volumn 29, Issue 1, 2009, Pages 3-28

  Bunch, Lennart ^a   Krogsgaard Larsen, Povl ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Ionotropic glutamate receptors; Kainic acid (kainate) receptors; Rational drug design; Receptor subtype selectivity; Structure activity relations

Indexed keywords

2 (CARBOXYCYCLOPROPYL)GLYCINE; 2 AZANORBORNANE 3 EXO,5 ENDO DICARBOXYLICACID; 2 CARBOXYPYRROLIDINE 3 ACETIC ACID; 3 CARBOXYISOXAZOLINYL PROLINE A; ACROMELIC ACID; ACROMELIC ACID A; ALLO KAINIC ACID; ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; ALPHA AMINO 5 TERT BUTYL 3 HYDROXY 4 ISOXAZOLEPROPIONIC ACID; AMPA RECEPTOR; BICYCLOOCTANE 2 AZA DICARBOXYLATE; C5' STEREOISOMER DOMOIC ACID; DIHYDROKAINIC ACID; DOMOIC ACID; DOMOILACTONE A,B; DYSIHERBAINE; GLUTAMIC ACID DERIVATIVE; ISO KAINIC ACID; ISODOMOIC ACID A C; ISODOMOIC ACID A H; KAINIC ACID; KAINIC ACID RECEPTOR; KAINIC ACID RECEPTOR AGONIST; KAINOID DERIVATIVE; METHYLGLUTAMIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEODYSIHERBAINE A; QUISQUALIC ACID; UNCLASSIFIED DRUG; UNINDEXED DRUG; WILLARDIINE;

CARBOXY TERMINAL SEQUENCE; CONFORMATIONAL TRANSITION; DRUG DESIGN; DRUG STRUCTURE; DRUG SYNTHESIS; LIGAND BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; REVIEW; STRUCTURE ACTIVITY RELATION;

ALANINE; ALGAE, RED; ANIMALS; BICYCLO COMPOUNDS, HETEROCYCLIC; BINDING SITES; KAINIC ACID; LIGANDS; QUISQUALIC ACID; RECEPTORS, KAINIC ACID; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 58849132420     PISSN: 01986325     EISSN: None     Source Type: Journal    
DOI: 10.1002/med.20133     Document Type: Review

References (148)

1. Meldrum BS. Glutamate as a neurotransmitter in the brain: Review of physiology and pathology. J Nutr 2000;130(4):1007S-1015S.
2. Bräuner-Osborne H, Egebjerg J, Nielsen EO, Madsen U, Krogsgaard-Larsen P. Ligands for glutamate receptors: Design and therapeutic prospects. J Med Chem 2000;43(14):2609-2645.
3. Wisden W, Seeburg PH. A complex mosaic of high-affinity kainate receptors in rat-brain. J Neurosci 1993;13(8):3582-3598.
4. Ferraguti F, Shigemoto R. Metabotropic glutamate receptors. Cell Tissue Res 2006;326(2):483-504.
5. Beart PM, O'Shea RD. Transporters for L-glutamate: An update on their molecular pharmacology and pathological involvement. Br J Pharmacol 2007;150(1):5-17.
6. Chaki S, Okubo T, Sekiguchi Y. Non-monoamine-based approach for the treatment of depression and anxiety disorders. Recent Patents CNS Drug Discov 2006;1(1):1-27.
7. Michelson D, Levine LR, Dellva MA, Mesters P, Schoepp DD, Dunayevich E, Tollefson GD. Clinical studies with mGluR2/3 agonists: LY354740 compared with placebo in patients with generalized anxiety disorder. Neuropharmacology 2005;49:257-257.
8. Kalivas PW. Cocaine and amphetamine-like psychostimulants: Neurocircuitry and glutamate neuroplasticity. Dialogues Clin Neurosci 2007;9(4):389-397.
9. Lea PMT, Faden AI. Metabotropic glutamate receptor subtype 5 antagonists MPEP and MTEP. CNS Drug Rev 2006;12(2):149-166.
10. Vikelis M, Mitsikostas DD. The role of glutamate and its receptors in migraine. CNS Neurol Disord Drug Targets 2007;6(4):251-257.
11. Muir KW. Glutamate-based therapeutic approaches: Clinical trials with NMDA antagonists. Curr Opin Pharmacol 2006;6(1):53-60.
12. Foster AC, Kemp JA. Glutamate- and GABA-based CNS therapeutics. Curr Opin Pharmacol 2006;6(1): 7-17.
13. Lees GJ. Pharmacology of AMPA/kainate receptor ligands and their therapeutic potential in neurological and psychiatric disorders. Drugs 2000;59(1):33-78.
14. Almeida A, Heales SJ, Bolanos JP, Medina JM. Glutamate neurotoxicity is associated with nitric oxide-mediated mitochondrial dysfunction and glutathione depletion. Brain Res 1998;790(1-2):209-216.
15. Alexander GM, Godwin DW. Metabotropic glutamate receptors as a strategic target for the treatment of epilepsy. Epilepsy Res 2006;71(1):1-22.
16. Zhorov BS, Tikhonov DB. Potassium, sodium, calcium and glutamate-gated channels: Pore architecture and ligand action. J Neurochem 2004;88(4):782-799.
17. Tikhonov DB. Ion channels of glutamate receptors: Structural modeling. Mol Membr Biol 2007;24(2):135-147.
18. Lerma J. Kainate receptor physiology. Curr Opin Pharmacol 2006;6(1):89-97.
19. Sommer B, Burnashev N, Verdoorn TA, Keinanen K, Sakmann B, Seeburg PH. A glutamate receptor channel with high-affinity for domoate and kainate. EMBO J 1992;11(4):1651-1656.
20. Cui CH, Mayer ML. Heteromeric kainate receptors formed by the coassembly of GluR5, GluR6, and Glu R7. J Neurosci 1999;19(19):8281-8291.
21. Porter RHP, Eastwood SL, Harrison PJ. Distribution of kainate receptor subunit mRNAs in human hippocampus, neocortex and cerebellum, and bilateral reduction of hippocampal GluR6 and KA2 transcripts in schizophrenia. Brain Res 1997;751(2):217-231.
22. Ruiz A, Sachidhanandam S, Utvik JK, Coussen F, Mulle C. Distinct subunits in heteromeric kainate receptors mediate ionotropic and metabotropic function at hippocampal mossy fiber synapses. J Neurosci 2005;25(50):11710-11718.
23. Rozas JL, Paternain AV, Lerma J. Noncanonical signaling by ionotropic kainate receptors. Neuron 2003;39(3):543-553.
24. Melyan Z, Lancaster B, Wheal HV. Metabotropic regulation of intrinsic excitability by synaptic activation of kainate receptors. J Neurosci 2004;24(19):4530-4534.
25. Fisahn A, Heinemann SF, McBain CJ. The kainate receptor subunit GluR6 mediates metabotropic regulation of the slow and medium AHP currents in mouse hippocampal neurones. J Physiol 2005;562(Pt 1):199-203.
26. Jones KA, Wilding TJ, Huettner JE, Costa AM. Desensitization of kainate receptors by kainate, glutamate and diastereomers of 4-methylglutamate. Neuropharmacology 1997;36(6):853-863.
27. Schiffer HH, Swanson GT, Heinemann SF. Rat GluR7 and a carboxy-terminal splice variant, GluR7b, are functional kainate receptor subunits with a low sensitivity to glutamate. Neuron 1997;19(5):1141-1146.
28. Huettner JE. Glutamate receptor channels in rat DRG neurons: Activation by kainate and quisqualate and blockade of desensitization by Con A. Neuron 1990;5(3):255-266.
29. Partin KM, Patneau DK, Winters CA, Mayer ML, Buonanno A. Selective modulation of desensitization at AMPA versus kainate receptors by cyclothiazide and concanavalin A. Neuron 1993;11(6):1069-1082.
30. Wong LA, Mayer ML. Differential modulation by cyclothiazide and concanavalin A of desensitization at native alpha-amino-3-hydroxy-5-methyl-4- isoxazolepropionic acid- and kainate-preferring glutamate receptors. Mol Pharmacol 1993;44(3):504-510.
31. Kantardjieff KA, Hochtl P, Segelke BW, Tao FM, Rupp B. Concanavalin A in a dimeric crystal form: Revisiting structural accuracy and molecular flexibility. Acta Crystallogr 2002;58(Pt 5):735-743.
32. Everts I, Villmann C, Hollmann M. N-Glycosylation is not a prerequisite for glutamate receptor function but Is essential for lectin modulation. Mol Pharmacol 1997;52(5):861-873.
33. Paternain AV, Rodriguez-Moreno A, Villarroel A, Lerma J. Activation and desensitization properties of native and recombinant kainate receptors. Neuropharmacology 1998;37(10-11):1249-1259.
34. Valluru L, Xu J, Zhu YL, Yang S, Contractor A, Swanson GT. Ligand binding is a critical requirement for plasma membrane expression of heteromeric kainate receptors. J Biol Chem 2005;280(7):6085-6093.
35. Isaac JTR, Mellor J, Hurtado D, Roche KW. Kainate receptor trafficking: Physiological roles and molecular mechanisms. Pharmacol Ther 2004;104(3):163-172.
36. Pinheiro P, Mulle C. Kainate receptors. Cell Tissue Res 2006;326(2):457-482.
37. Lerma J, Paternain AV, Rodriguez-Moreno A, Lopez-Garcia JC. Molecular physiology of kainate receptors. Physiol Rev 2001;81(3):971-998.
38. Evrard-Todeschi N, Gharbi-Benarous J, Cosse-Barbi A, Thirot G, Girault JP. Conformational analysis of 2-(carboxycyclopropyl)glycine agonists of glutamate receptors in aqueous solution using a combination of NMR and molecular modelling experiments and charge calculations. J Chem Soc Perkin Trans 2 1997 (12):2677-2689.
39. Davies J, Evans RH, Francis AA, Jones AW, Smith DAS, Watkins JC. Conformational aspects of the actions of some peperidine dicarboxylic-acids at excitatory amino-acid receptors in the mammalian and amphibian spinal-cord. Neurochem Res 1982;7(9):1119-1133.
40. Conti P, De Amici M, De Sarro G, Rizzo M, Stensbol TB, Brauner-Osborne H, Madsen U, Toma L, De Micheli C. Synthesis and enantiopharmacology of new AMPA-kainate receptor agonists. J Med Chem 1999;42(20):4099-4107.
41. Kawai M, Horikawa Y, Ishihara T, Shimamoto K, Ohfune Y. 2-(Carboxycyclopropyl) glycines - Binding, neurotoxicity and induction of intracellular free Ca-2+ increase. Eur J Pharmacol 1992;211(2):195-202.
42. Bunch L, Nielsen B, Jensen AA, Brauner-Osborne H. Rational design and enantioselective synthesis of (1R,4S,5R,6S)-3-azabicyclo[3.3.0]octane-4,6- dicarboxylic acid - A novel inhibitor at human glutamate transporter subtypes 1, 2, and 3. J Med Chem 2006;49(1):172-178.
43. Bunch L, Liljefors T, Greenwood JR, Frydenvang K, Bräuner-Osborne H, Krogsgaard-Larsen P, Madsen U. Rational design, synthesis, and pharmacological evaluation of 2-azanorbornane-3-exo,5-endodicarboxylic acid: A novel conformationally restricted glutamic acid analogue. J Org Chem 2003; 68(4):1489-1495.
44. Nielsen PA, Liljefors T. Conformational analysis of kainate in aqueous solution in relation to its binding to AMPA and kainic acid receptors. J Comput Aided Mol Des 2001;15(8):753-763.
45. Naur P, Vestergaard B, Skov LK, Egebjerg J, Gajhede M, Kastrup JS. Crystal structure of the kainate receptor GluR5 ligand-binding core in complex with (S)-glutamate. FEBS Lett 2005;579(5):1154-1160.
46. Hayashi Y, Tanabe Y, Aramori I, Masu M, Shimamoto K, Ohfune Y, Nakanishi S. Agonist analysis of 2-(carboxycyclopropyl)glycine isomers for cloned metabotropic glutamate receptor subtypes expressed in Chinese hamster ovary cells. Br J Pharmacol 1992;107(2):539-543.
47. Armstrong N, Gouaux E. Mechanisms for Activation and Antagonism of an AMPA-Sensitive Glutamate Receptor: Crystal Structures of the GluR2 Ligand Binding Core. Neuron 2000;28(1):165-181.
48. Hald H, Naur P, Pickering DS, Sprogoe D, Madsen U, Timmermann DB, Ahring PK, Liljefors T, Schousboe A, Egebjerg J, Gajhede M, Kastrup JS. Partial agonism and antagonism of the ionotropic glutamate receptor iGLu R5: Structure of the ligand-binding core in complex with domoric acid and 2-amino-3-[5-tert-butyl-3- (phosphonomethoxy)-4-isoxazolyl]propionic acid. J Biol Chem 2007;282(35): 25726-25736.
49. Alt A, Weiss B, Ogden AM, Knauss JL, Oler J, Ho K, Large TH, Bleakman D. Pharmacological characterization of glutamatergic agonists and antagonists at recombinant human homomeric and heteromeric kainate receptors in vitro. Neuropharmacology 2004;46(6):793-806.
50. Swanson GT, Gereau RWT, Green T, Heinemann SF. Identification of amino acid residues that control functional behavior in GluR5 and GluR6 kainate receptors. Neuron 1997;19(4):913-926.
51. Mayer ML, Ghosal A, Dolman NP, Jane DE. Crystal structures of the kainate receptor GluR5 ligand binding core dimer with novel GluR5-selective antagonists. J Neurosci 2006;26(11):2852-2861.
52. Mayer ML. Crystal structures of the GluR5 and GluR6 ligand binding cores: Molecular mechanisms underlying kainate receptor selectivity. Neuron 2005;45(4):539-552.
53. Pedregal C, Collado I, Escribano A, Ezquerra J, Dominguez C, Mateo AI, Rubio A, Baker SR, Goldsworthy J, Kamboj RK, Ballyk BA, Hoo K, Bleakman D. 4-alkyl- and 4-cinnamylglutamic acid analogues are potent GluR5 kainate receptor agonists. J Med Chem 2000;43(10):1958-1968.
54. Nanao MH, Green T, Stern-Bach Y, Heinemann SF, Choe S. Structure of the kainate receptor subunit GluR6 agonist-binding domain complexed with domoic acid. Proc Natl Acad Sci 2005;102(5):1708-1713.
55. Nielsen BB, Pickering DS, Greenwood JR, Brehm L, Gajhede M, Schousboe A, Kastrup JS. Exploring the GluR2 ligand-binding core in complex with the bicyclical AMPA analogue (S)-4-AHCP. FEBS J 2005;272(7):1639-1648.
56. Frandsen A, Pickering DS, Vestergaard B, Kasper C, Nielsen BB, Greenwood JR, Campiani G, Fattorusso C, Gajhede M, Schousboe A, Kastrup JS. Tyr702 is an important determinant of agonist binding and domain closure of the ligand-binding core of Glu R2. Mol Pharmacol 2005;67(3):703-713.
57. Sagot E, Pickering DS, Pu X, Umberti M, Stensbøl TB, Nielsen B, Chapelet M, Bolte J, Gefflaut T, Bunch L. Chemo-enzymatic synthesis of a series of 2,4-syn-functionalized (S)-glutamate analogues: Newinsight into the structure-activity-relation of ionotropic glutamate receptor subtypes 5,6 and 7. J Med Chem 2008;51(14):4093-4103.
58. Murakami S, Takemoto T, Shimizu Z. Studies on the effective principles of digena-simplex AQ. 1. Separation of the effective fraction by liquid chromatography. Yakugaku Zasshi J Pharm Soc Jpn 1953;73(9):1026-1028.
59. Impellizzeri G, Mangiafico S, Oriente G, Piattelli M, Sciuto S, Fattorusso E, Magno S, Santacroce C, Sica D. Constituents of red algae. 1. Amino-acid and low-molecular-weight carbohydrates of some marine red algae. Phytochemistry 1975;14(7):1549-1557.
60. Balansard G, Pellegrini M, Cavalli C, Timondavid P, Gasquet M, Boudon G. Diagnosis and anthelmintic action of Alsidium-helminthocorton kutzing (Corsic-moss), of Jania-Rubens lamour and of corallina-officinalis L. Ann Pharm Fr 1983;41(1):77-86.
61. Nitta I, Watase H, Tomiie Y. Structure of kainic acid and its isomer, allokainic acid. Nature 1958;181(4611):761-762.
62. Oppolzer W, Andres H. Total synthesis of alpha-kainic acid by an intra-molecular ene reaction. Helv Chim Acta 1979;62(7):2282-2284.
63. Oppolzer W, Thirring K. Enantioselective synthesis and absolute-configuration of (-)-alpha-kainic acid. J Am Chem Soc 1982;104(18):4978-4979.
64. Cooper J, Knight DW, Gallagher PT. An enantiospecific total synthesis of (-)-alpha-kainic acid. J Chem Soc Chem Commun 1987(16):1220-1222.
65. Takano S, Iwabuchi Y, Ogasawara K. A concise enantioselective route to (-)-kainic acid from (S)-2-(benzyloxymethyl)oxirane. J Chem Soc Chem Commun 1988(17):1204-1206.
66. Barco A, Benetti S, Pollini GP, Spalluto G, Zanirato V. A new enantioselective route to kainoids - Application to the formal synthesis of (-)-alpha-kainic acid. J Chem Soc Chem Commun 1991(6):390-391.
67. Cooper J, Knight DW, Gallagher PT. Total synthesis of (-)-alpha-kainic acid. J Chem Soc Perkin Trans 1 1992 (5):553-559.
68. Yoo SE, Lee SH. A total synthesis of (-)-alpha-kainic acid involving a Pauson-Khand reaction as the key step. J Org Chem 1994;59(23):6968-6972.
69. Bachi MD, Melman A. Enantioselective total synthesis of (-)-alpha-kainic acid through free radical cyclization of an alkenyl monothioformimide. J Org Chem 1997;62(6):1896-1898.
70. Miyata O, Ozawa Y, Ninomiya I, Naito T. An enantioselective synthesis of (-)-alpha-kainic acid via thiyl radical addition-cyclization-elimination reaction. Synlett 1997 (3):275-276.
71. Kawamura M, Ogasawara K. A new enantiocontrolled route to (-)-kainic acid. Heterocycles 1997;44:129-132.
72. Nakada Y, Sugahara T, Ogasawara K. An enantioconvergent route to (-)-kainic acid. Tetrahedron Lett 1997;38(5):857-860.
73. Chevliakov MV, Montgomery J. A stereodivergent approach to (-)-alpha-kainic acid and (+)-alpha-allokainic acid utilizing the complementarity of alkyne and allene cyclizations. J Am Chem Soc 1999;121(48):11139-11143.
74. Campbell AD, Raynham TM, Taylor RJK. The stereoselective preparation of substituted pyrrolidines using titanium- and zirconium-mediated diene metallabicyclisation methodology: the total synthesis of (-)-alpha-kainic acid. J Chem Soc Perkin Trans 1 2000; (19):3194-3204.
75. Nakagawa H, Sugahara T, Ogasawara K. A concise route to (-)-kainic acid. Org Lett 2000;2(20):3181-3183.
76. Clayden J, Tchabanenko K. Synthesis of (+/-)-kainic acid by dearomatising cyclisation of a lithiated N-benzyl p-anisamide. Chem Commun 2000; (4):317-318.
77. Xia Q, Ganem B. Asymmetric total synthesis of (-)-alpha-kainic acid using an enantioselective, metal-promoted ene cyclization. Org Lett 2001;3(3):485-487.
78. Clayden J, Menet CJ, Tchabanenko K. Synthesis of (-)-kainic acid using chiral lithium amides in an asymmetric dearomatizing cyclization. Tetrahedron 2002;58(23):4727-4733.
79. Anderson JC, Whiting M. Total synthesis of (+/-)-kainic acid with an aza-[2,3]-Wittig sigmatropic rearrangement as the key stereochemical determining. J Org Chem 2003;68(16):6160-6163.
80. Martinez MM, Hoppe D. Total synthesis of (-)-alpha-kainic acid by (-)-sparteine-mediated asymmetric deprotonation-cycloalkylation. Org Lett 2004;6(21):3743-3746.
81. Poisson JF, Orellana A, Greene AE. Stereocontrolled synthesis of (-)-kainic acid from trans-4-hydroxy-L-proline. J Org Chem 2005;70(26):10860- 10863.
82. Hodgson DM, Hachisu S, Andrews MD. Synthesis of alpha-kainic acid from a 7-azabicyclo[2.2.1]heptadiene by tandem radical addition-homoallylic radical rearrangement. Org Lett 2005;7(5):815-817.
83. Hodgson DM, Hachisu S, Andrews MD. Stereocontrolled syntheses of kainoid amino acids from 7-azabicyclo[2.2.1]heptadienes using tandem radical addition-homoallylic radical rearrangement. J Org Chem 2005;70(22):8866-8876.
84. Chalker JM, Yang A, Deng K, Cohen T. Two syntheses of (-)-kainic acid via highly stereoselective zincene cyclizations. Org Lett 2007;9(19):3825-3828.
85. Takeuchi H, Watanabe K, Nomoto K, Ohfune Y, Takemoto T. Effects of alpha-kainic acid, domoric acid and their derivatives on the Molluscan giant-neuron sensitive to beta-hydroxy-L-glutamic acid. Eur J Pharmacol 1984;102(2):325-332.
86. Baker SR, Bleakman D, Ezquerra J, Ballyk BA, Deverill M, Ho K, Kamboj RK, Collado I, Dominguez C, Escribano A, Mateo AI, Pedregal C, Rubio A. 4-alkylidenyl glutamic acids, potent and selective GluR5 agonists. Bioorg Med Chem Lett 2000;10(16):1807-1810.
87. Shimamoto K, LeBrun B, Yasuda-Kamatani Y, Sakaitani M, Shigeri Y, Yumoto N, Nakajima T. DL-threobeta-benzyloxyaspartate, a potent blocker of excitatory amino acid transporters. Mol Pharmacol 1998;53(2):195-201.
88. Sonnenberg JD, Koch HP, Willis CL, Bradbury F, Dauenhauer D, Bridges RJ, Chamberlin AR. The role of the C-4 side chain of kainate and dihydrokainate in EAA receptor and transporter selectivity. Bioorg Med Chem Lett 1996;6(13):1607-1612.
89. Jensen AA, Bräuner-Osborne H. Pharmacological characterization of human excitatory amino acid transporters EAAT1, EAAT2 and EAAT3 in a fluorescence-based membrane potential assay. Biochem Pharmacol 2004;67(11):2115-2127.
90. Hashimoto K, Matsumoto T, Nakamura K, Ohwada S, Ohuchi T, Horikawa M, Konno K, Shirahama H. Molecular orbital calculation for the model compounds of kainoid amino acids, agonists of excitatory amino acid receptors. Does the kainoid C4-substituent directly interact with the receptors? Bioorg Med Chem 2002;10(5):1373-1379.
91. Pentikainen OT, Settimo L, Keinanen K, Johnson MS. Selective agonist binding of (S)-2-amino-3-(3-hydroxy-5-methyl-4-isoxazolyl)propionic acid (AMPA) and 2S-(2 alpha,3 beta,4 beta)-2-carboxy-4-(1-methylethenyl)-3-pyrrolidineacetic acid (kainate) receptors: A molecular modeling study. Biochem Pharmacol 2003;66(12):2413-2425.
92. Clayden J, Read B, Hebditch KR. Chemistry of domoic acid, isodomoic acids, and their analogues. Tetrahedron 2005;61(24):5713-5724.
93. Carcache LM, Rodriguez J, Rein KS. The structural basis for kainoid selectivity at AMPA receptors revealed by low-mode docking calculations. Bioorg Med Chem 2003;11(4):551-559.
94. Nanao MH, Green T, Stern-Bach Y, Heinemann SF, Choe S. Structure of the kainate receptor subunit GluR6 agonist-binding domain complexed with domoic acid. Proc Natl Acad Sci USA 2005;102(5):1708-1713.
95. Jin RS, Banke TG, Mayer ML, Traynelis SF, Gouaux E. Structural basis for partial agonist action at ionotropic glutamate receptors. Nature Neurosci 2003;6(8):803-810.
96. Hampson DR, Huang XP, Wells JW, Walter JA, Wright JL. Interaction of domoic acid and several derivatives with kainic acid and AMPA binding sites in rat brain. Eur J Pharmacol 1992;218(1):1-8.
97. Maeda M, Kodama T, Tanaka T, Yoshizumi H, Takemoto T, Nomoto K, Fujita T. Strucutre of domoilactone-A and domoilactone-B, novel amino acids from the red alga, Chondria-armata. Tetrahedron Lett 1987;28(6):633-636.
98. Kwak S, Aizawa H, Ishida M, Shinozaki H. New, potent kainate derivates - Comparison of their affinity for [H-3] kainate and [H-3] AMPA binding-sites. Neurosci Lett 1992;139(1):114-117.
99. Smith AL, McIlhinney RAJ. Effects of acromelic acid-A on the binding of [H-3] kainic acid and [H-3] AMPA to rat-brain synaptic plasma-membranes. Br J Pharmacol 1992;105(1):83-86.
100. Fushiya S, Sato S, Kanazawa T, Kusano G, Nozoe S. Acromelic acid-C - A new toxic constituent of Clitocybe-acromelalga-An efficient isolation of acromelic acids. Tetrahedron Lett 1990;31(27):3901-3904.
101. Fushiya S, Sato S, Kera Y, Nozoe S. Isolation of acromelic aicd-D and acid-E from Clitocybe-acromelalga. Heterocycles 1992;34(7):1277-1280.
102. Konno K, Shirahama H, Matsumoto T. Isolation and structure of acromelic acid-A and acid-B - New kainoids of clitocybe-acromelalga. Tetrahedron Lett 1983;24(9):939-942.
103. Baldwin JE, Fryer AM, Pritchard GJ. Parallel synthesis of novel heteroaromatic acromelic acid analogues from kainic acid. J Org Chem 2001;66(8):2588-2596.
104. Conway GA, Park JS, Maggiora L, Mertes MP, Galton N, Michaelis EK. Palladium(II)-catalyzed olefincoupling reactions of kainic acid - Effects of substitution on the isopropenyl group on receptor-binding. J Med Chem 1984;27(1):52-56.
105. da Silva KP, Godoi MN, Correia CRD. Regio- and stereoselective Heck arylations of N-carbomethoxy-L-3-dehydroproline methyl ester with arenediazonium salts. Total synthesis of neuroexcitatory aryl kainoids. Org Lett 2007;9(15):2815-2818.
106. Baldwin JE, Pritchard GJ, Williamson DS. The synthesis of 4-arylsulfanyl-substituted kainoid analogues from trans-4-hydroxy-L-proline. Tetrahedron 2001;57(37):7991-7997.
107. Soen M, Minami T, Tatsumi S, Mabuchi T, Furuta K, Maeda M, Suzuki M, Ito S. A synthetic kainoid, (2S,3R,4R)-3-carboxymethyl-4-(phenylthio) pyrrolidine-2-carboxylic acid (PSPA-1) serves as a novel anti-allodynic agent for neuropathic pain. Eur J Pharmacol 2007;575(1-3):75-81.
108. Sun P, Wang GX, Furuta K, Suzuki M. Synthesis of a bis-azido analogue of acromelic acid for radioisotope-free photoaffinity labeling and biochemical studies. Bioorg Med Chem Lett 2006;16(9):2433-2436.
109. Collado I, Ezquerra J, Mateo AI, Pedregal C, Rubio A. Stereocontrolled synthesis of 5 alpha- and 5 betasubstituted kainic acids. J Org Chem 1999;64(12):4304-4314.
110. Collado I, Ezquerra J, Mateo AI, Rubio A. Stereocontrolled synthesis of 4-substituted (+/-)-kainic acids. J Org Chem 1998;63(6):1995-2001.
111. Kozikowski AP, Fauq AH. Probing the topography of kainate recognition sites - Synthesis of a novel oxetane containing kainic acid analog. Tetrahedron Lett 1990;31(21):2967-2970.
112. Hanessian S, Ninkovic S, Reinhold U. The synthesis of 4,5-methano congeners of alpha-kainic and alpha-allo-kainic acids as probes for glutamate receptors. Tetrahedron Lett 1996;37(50):8971-8974.
113. Peichuan P, Shengdin F, Chunchao T. Chemical constituents of shihchuntze, quisqualis-indical L. 2. Structure of quisqualic acid. Scientia Sinica 1976;19(5):691-701.
114. Takemoto T, Nakajima T, Arihara S, Koike K. Studies on the constituents of quisqualis-fructus .2. Structure of quisqualic acid. Yakugaku Zasshi J Pharm Soc Jpn 1975;95(3):326-332.
115. Takemoto T, Koike K, Nakajima T, Arihara S. Studies on the constituents of quisqualis-fructus. 3. Synthesis of quisqualic acid and related compounds. Yakugaku Zasshi J Pharm Soc Jpn 1975;95(4):448-452.
116. Flippen JL, Gilardi RD. Quisqualic acid. Acta Crystallogr B 1976;32:951-953.
117. Kinney WA, Lee NE, Garrison DT, Podlesny EJ Jr, Simmonds JT, Bramlett D, Notvest RR, Kowal DM, Tasse RP. Bioisosteric replacement of the alpha-amino carboxylic acid functionality in 2-amino-5-phosphonopentanoic acid yields unique 3,4-diamino-3-cyclobutene-1,2-dione containing NMDA antagonists. J Med Chem 1992;35(25):4720-4726.
118. Shinozaki H, Shibuya I. Effects of kainic acid analogs on crayfish opener muscle. Neuropharmacology 1976;15(2):145-147.
119. Brauner-Osborne H, Krogsgaard-Larsen P. Pharmacology of (S)-homoquisqualic acid and (S)-2-amino-5-phosphonopentanoic acid [(S)-AP5] at cloned metabotropic glutamate receptors. Br J Pharmacol 1998;123(2):269-274.
120. Subasinghe N, Schulte M, Roon RJ, Koerner JF, Johnson RL. Quisqualic acid analogs - Synthesis of beta-heterocyclic 2-aminopropanoic acid-derivatices and their activity at novel quisqualate-sensitized site. J Med Chem 1992;35(24):4602-4607.
121. Boden P, Bycroft BW, Chhabra SR, Chiplin J, Crowley PJ, Grout RJ, King TJ, McDonald E, Rafferty P, Usherwood PNR. The action of natural and synthetic isomers of quisqualic acid at the well-defined glutamatergic synapse. Brain Res 1986;385(2):205-211.
122. Gmelin R. DIie frein aminosauren der samen con acacia-willardiana (Mimosaceae) - Isolierung von willardiin, einer neuen pflanzlichen aminosaure, vermutlich L-uracil-[beta-(alpha-amino-propionsaure)]-(3). H-S Z Physiol Chem 1959;316(3-6):164-169.
123. Kjaer A, Knudsen A, Larsen PO. Amino acid studies .4. structure and synthesis of plant amino acid willardiine [3-(1-uracyl)-L-alanine]. Acta Chem Scand 1961;15(5):1193-1195.
124. Wong LA, Mayer ML, Jane DE, Watkins JC. Willardiines differentiate agonist binding sites for kainateversus AMPA-preferring glutamate receptors in DRG and hippocampal neurons. J Neurosci 1994;14(6): 3881-3897.
125. Jane DE, Hoo K, Kamboj R, Deverill M, Bleakman D, Mandelzys A. Synthesis of willardiine and 6-azawillardiine analogs: Pharmacological characterization on cloned homomeric human AMPA and kainate receptor subtypes. J Med Chem 1997;40(22):3645-3650.
126. Hill RA, Wallace LJ, Miller DD, Weinstein DM, Shams G, Tai H, Layer RT, Willins D, Uretsky NJ, Danthi SN. Structure-activity studies for alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropanoic acid receptors: Acidic hydroxyphenylalanines. J Med Chem 1997;40(20):3182-3191.
127. Sanders JM, Pentikainen OT, Settimo L, Pentikainen U, Shoji M, Sasaki M, Sakai R, Johnson MS, Swanson GT. Determination of binding site residues responsible for the subunit selectivity of novel marine-derived compounds on kainate receptors. Mol Pharmacol 2006;69(6):1849-1860.
128. Lash LL, Sanders JM, Akiyama N, Shoji M, Postila P, Pentikainen OT, Sasaki M, Sakai R, Swanson GT. Novel analogs and stereoisomers of the marine toxin neodysiherbaine with specificity for kainate receptors. J Pharmacol Exp Ther 2008;324(2):484-496.
129. Sakai R, Swanson GT, Shimamoto K, Green T, Contractor A, Ghetti A, Tamura-Horikawa Y, Oiwa C, Kamiya H. Pharmacological properties of the potent epileptogenic amino acid dysiherbaine, a novel glutamate receptor agonist isolated from the marine sponge Dysidea herbacea. J Pharmacol Exp Ther 2001;296(2):650-658.
130. Swanson GT, Green T, Sakai R, Contractor A, Che W, Kamiya H, Heinemann SF. Differential activation of individual subunits in heteromeric kainate receptors. Neuron 2002;34(4):589-598.
131. Sanders JM, Ito K, Settimo L, Pentikainen OT, Shoji M, Sasaki M, Johnson MS, Sakai R, Swanson GT. Divergent pharmacological activity of novel marine-derived excitatory amino acids on glutamate receptors. J Pharmacol Exp Ther 2005;314(3):1068-1078.
132. Shoji M, Akiyama N, Tsubone K, Lash LL, Sanders JM, Swanson GT, Sakai R, Shimamoto K, Oikawa M, Sasaki M. Total synthesis and biological evaluation of neodysiherbaine A and analogues. J Org Chem 2006;71(14):5208-5220.
133. Lauridsen J, Honore T, Krogsgaardlarsen P. Ibotenic acid analogs - Synthesis, molecular flexibility, and in vitro activity of agonists and antagonists at central glutamic-acid receptors. J Med Chem 1985;28(5):668-672.
134. Clarke VRJ, Ballyk BA, Hoo KH, Mandelzys A, Pellizzari A, Bath CP, Thomas J, Sharpe EF, Davies CH, Ornstein PL, Schoepp DD, Kamboj RK, Collingridge GL, Lodge D, Bleakman D. A hippocampal GluR5 kainate receptor regulating inhibitory synaptic transmission. Nature 1997;389(6651):599-603.
135. Krogsgaardlarsen P, Nielsen EO, Curtis DR. Ibotenic acid analogs - Synthesis and biological and in vitro activity of conformationally restricted agonists at central excitatory amino-acid receptors. J Med Chem 1984;27(5):585-591.
136. Vogensen SB, Jensen HS, Stensbol TB, Frydenvang K, Bang-Andersen B, Johansen TN, Egebjerg J, Krogsgaard-Larsen P. Resolution, configurational assignment, and enantiopharmacology of 2-amino-3-[3-hydroxy-5-(2-methyl-2H- tetrazol-5-yl)isoxazol-4-yl]propionic acid, a potent GluR3-and GluR4-preferring AMPA receptor agonist. Chirality 2000;12(10):705-713.
137. Stensbol TB, Jensen HS, Nielsen B, Johansen TN, Egebjerg J, Frydenvang K, Krogsgaard-Larsen P. Stereochemistry and molecular pharmacology of (S)-thio-ATPA, a new potent and selective GluR5 agonist. Eur J Pharmacol 2001;411(3):245-253.
138. BangAndersen B, Lenz SM, Skjaerbaek N, Soby KK, Hansen HO, Ebert B, Bogeso KP, KrogsgaardLarsen P. Heteroaryl analogues of AMPA. Synthesis and quantitative structure-activity relationships. J Med Chem 1997;40(18):2831-2842.
139. Falch E, Brehm L, Mikkelsen I, Johansen TN, Skjaerbaek N, Nielsen B, Stensbol TB, Ebert B, Krogsgaard-Larsen P. Heteroaryl analogues of AMPA. 2. Synthesis, absolute stereochemistry, photochemistry, and structure-activity relationships. J Med Chem 1998;41(14):2513-2523.
140. Stensbol TB, Borre L, Johansen TN, Egebjerg J, Madsen U, Ebert B, Krogsgaard-Larsen P. Resolution, absolute stereochemistry and molecular pharmacology of the enantiomers of ATPA. Eur J Pharmacol 1999;380(2-3):153-162.
141. Brehm L, Greenwood JR, Hansen KB, Nielsen B, Egebjerg J, Stensbol TB, Brauner-Osborne H, Slok FA, Kronborg TTA, Krogsgaard-Larsen P. (S)-2-amino-3-(3-hydroxy-7,8-dihydro-6H-cyclohepta[d]isoxazol-4-yl)propi onic acid, a potent and selective agonist at the GluR5 subtype of ionotropic glutamate receptors. Synthesis, modeling, and molecular pharmacology. J Med Chem 2003;46(8):1350-1358.
142. Todeschi N, GharbiBenarous J, Acher F, Azerad R, Girault JP. Conformational analysis by NMR spectroscopy and molecular simulation in water of methylated glutamic acids, agonists at glutamate receptors. J Chem Soc Perkin Trans 2 1996 (7):1337-1351.
143. Todeschi N, GharbiBenarous J, Acher F, Larue V, Pin JP, Bockaert J, Azerad R, Girault JP. Conformational analysis of glutamic acid analogues as probes of glutamate receptors using molecular modelling and NMP methods. Comparison with specific agonists. Bioorg Med Chem 1997;5(2):335-352.
144. Zhou LM, Gu ZQ, Costa AM, Yamada KA, Mansson PE, Giordano T, Skolnick P, Jones KA. (2S,4R)-4-Methylglutamic acid (SYM 2081):Aselective, high-affinity ligand for kainate receptors. J Pharmacol Exp Ther 1997;280(1):422-427.
145. BraunerOsborne H, Nielsen B, Stensbol TB, Johansen TN, Skjaerbaek N, KrogsgaardLarsen P. Molecular pharmacology of 4-substituted glutamic acid analogues at ionotropic and metabotropic excitatory amino acid receptors. Eur J Pharmacol 1997;335(2-3):R1-R3.
146. Gu ZQ, Hesson DP, Pelletier JC, Maccecchini ML, Zhou LM, Skolnick P. Synthesis, resolution, and biological evaluation of the 4-stereoisomers of 4-methylglutamic acid - Selective probes of kainate receptors. J Med Chem 1995;38(14):2518-2520.
147. Bunch L, Johansen TH, Bräuner-Osborne H, Stensbol TB, Johansen TN, Krogsgaard-Larsen P, Madsen U. Synthesis and receptor binding affinity of newselective GluR5 ligands. Bioorg Med Chem 2001;9(4):875-879.
148. Valgeirsson J, Christensen JK, Kristensen AS, Pickering DS, Nielsen B, Fischer CH, Brauner-Osborne H, Nielsen EO, Krogsgaard-Larsen P, Madsen U. Synthesis and in vitro pharmacology at AMPA and kainate preferring glutamate receptors of 4-heteroarylmethylidene glutamate analogues. Bioorg Med Chem 2003;11(20):4341-4349.